Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications
- 1 January 2005
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 1 (1) , 93-106
- https://doi.org/10.2174/1573399052952631
Abstract
Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the development and progression of diabetic micro- and macroangiopathy. Among various metabolic derangements implicated in the pathogenesis of diabetic vascular complication, advanced glycation end product (AGE) hypothesis is most compatible with the theory of hyperglycemic memory. In this review, we discuss the molecular mechanisms of diabetic vascular complication, specially focusing on AGEs and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in this devastating disorder are also discussed here.Keywords
This publication has 69 references indexed in Scilit:
- Inhibition of protein kinase C might be harmful to diabetic retinopathyMedical Hypotheses, 2004
- Pigment epithelium-derived factor inhibits TNF-α-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generationJournal of Molecular and Cellular Cardiology, 2004
- Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivoMedical Hypotheses, 2004
- Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproductsPublished by Elsevier ,2003
- Role of endothelial dysfunction in insulin resistanceThe American Journal of Cardiology, 2003
- Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient miceAtherosclerosis, 2003
- Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative propertiesMicrovascular Research, 2003
- Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathyNature Medicine, 2003
- Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generationDiabetologia, 2003
- Advanced Glycation End Products-Induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor in Bovine Retinal PericytesBiochemical and Biophysical Research Communications, 2002